Keros Therapeutics (KROS) Insider Trading & Ownership $13.35 -0.14 (-1.04%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Keros Therapeutics (NASDAQ:KROS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage22.90%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$9.46MNumber OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$11.00M Get KROS Insider Trade Alerts Want to know when executives and insiders are buying or selling Keros Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KROS Insider Buying and Selling by Quarter Keros Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/9/2025Adar1 Capital Management, LlcMajor ShareholderBuy934,258$10.13$9,464,033.54 8/13/2024Carl L GordonDirectorSell250,000$44.01$11,002,500.00 (Data available from 1/1/2013 forward) KROS Insider Trading Activity - Frequently Asked Questions Who is on Keros Therapeutics' Insider Roster? The list of insiders at Keros Therapeutics includes Adar1 Capital Management, Llc, Carl L Gordon, Jennifer Lachey, and Keith Regnante. Learn more on insiders at KROS. What percentage of Keros Therapeutics stock is owned by insiders? 22.90% of Keros Therapeutics stock is owned by insiders. Learn more on KROS's insider holdings. Which Keros Therapeutics insiders have been buying company stock? The following insider purchased KROS shares in the last 24 months: Adar1 Capital Management, Llc ($9,464,033.54). How much insider buying is happening at Keros Therapeutics? Insiders have purchased a total of 934,258 KROS shares in the last 24 months for a total of $9,464,033.54 bought. Which Keros Therapeutics insiders have been selling company stock? The following insider sold KROS shares in the last 24 months: Carl L Gordon ($11,002,500.00). How much insider selling is happening at Keros Therapeutics? Insiders have sold a total of 250,000 Keros Therapeutics shares in the last 24 months for a total of $11,002,500.00 sold. More Insider Trading Tools from MarketBeat Related Companies ARWR Insider Transactions VCEL Insider Transactions DNLI Insider Transactions RXRX Insider Transactions NAMS Insider Transactions KNSA Insider Transactions APGE Insider Transactions CGON Insider Transactions IDYA Insider Transactions AGIO Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Top Insider Sells From Q2: Buy, Sell, or Hold?3 Hot Trades for Insiders, But Are They Good Buys for Investors?Insiders Chase Income and Stability in American Tower—Here’s Why3 Tech Stocks With High and Rising Institutional Interest3 Summer Stocks With Insider Buying and Analyst Support This page (NASDAQ:KROS) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.